Insightful paper on therapeutic R&D spending in oncology. Authors conclude that better predictive models applied earlier in drug development would help avoid costly late-stage failures.

This is why I moved to Toronto to start Altis Labs. bloomberg.com/news/articles/…

A big thank you to our clinical partners Trillium Health Partners and U Calgary as well as the DIGITAL for helping us accelerate biomedical research.

Thank you FierceBiotech for covering our product launch! #ai #clinicaltrials #digitaltwins #deeplearning #nsclc fiercebiotech.com/cro/altis-lead…

Big news for the ecosystem! Altis Labs is launching their Digital Twin AI models with AstraZeneca and Bayer | Pharmaceuticals, accelerating clinical trials and increasing reliability. Congratulations to the entire team!🎉 Read more: ow.ly/e0aG50PCRWx

Excellent discussion today about the promise of real-world imaging data in oncology drug development to help generate better clinical evidence. Thank you Friends of Cancer Research for hosting!

Looking forward to many interesting conversations!

Excellent article by Zach Brennan at Endpoints News on how U.S. FDA is "increasingly calling for more robust overall survival data that can prove treatments help patients live longer." endpts.com/fda-pushes-can…

Important analysis published by FDA evaluating the utility of PFS and ORR.

"The goal of what they call 'common-sense oncology' is to prioritize treatments that meaningfully improve survival and quality of life." This is why we need clinically meaningful endpoints beyond PFS and ORR. Clinical development resources need to be allocated to programs that

Fantastic article by Allison DeAngelis on how our team at Altis Labs is using AI to transform clinical trials – thank you for the shoutout! If sponsors focus too heavily on reductionist tumor size measurements to guesstimate efficacy, “they might be pushing a drug into

Biopharma companies are beginning to turn to AI to enroll people in clinical trials. trib.al/0R11vzW

Join me on Wednesday for a discussion about Digital Twins in oncology trials here in Toronto at #MaRSImpactHealth, Canada's largest healthcare conference. The panel will include our partners at Bayer | Pharmaceuticals and will be moderated by science journalist Ayesha Rashid. When:

Excited to be back in NYC next week for the AI x Bio Summit!

The Altis Labs team is excited to announce that two abstracts have been accepted at ESMO - Eur. Oncology for poster presentation this year, illustrating our latest research with biopharma partners and research collaborators. Please reach out if you're headed to Barcelona for #ESMO24 this

I wish more people in my industry would agree that overall survival (OS) should be the primary endpoint for regular cancer drug approvals. We should hold ourselves to the highest, patient-centric standard.

Thank you Brittany Trang for featuring the recent results from AstraZeneca's evaluation of our AI models. We have a lot more work to do, but we're excited to begin to showcase how AI can accelerate clinical development with a stronger predictor of overall survival, the gold

We're proud to share that results from AstraZeneca's evaluation of our AI-powered External Control Arm were presented at #ISPOR2025 today. AZ's analysis showed that our ECA replicated survival outcomes of the control arm and preserved the observed treatment effect.

At the Canadian Breast Cancer Symposium, we presented a first glimpse of IPRO’s ability to generalize across cancer types. In this study, our AI model analyzed pretreatment breast cancer scans having trained solely on lung cancer data. Remarkably, IPRO stratified survival

Delighted to announce our partnership with Johnson & Johnson!